Publications by authors named "C Willemien Menke-van der Houven van Oordt"
Pharmacokinetic analysis and simplified uptake measures for tumour lesion [F]F-AraG PET imaging in patients with non-small cell lung cancer.
Eur J Nucl Med Mol Imaging
October 2024
Article Synopsis
- This study looks at a new imaging tracer called [F]F-AraG, which helps scientists understand how cancer and the immune system interact, particularly in lung cancer patients.
- Researchers tested this tracer in 13 patients to figure out the best way to measure how much of it gets taken up by tumors over time.
- The results showed that the 2T3k model was the best for understanding how the tracer works, and two specific measurements (TBR and TPR) were very useful for comparing results across different time periods.
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m, day 1 + 2) and Rituximab (375 mg/m, day 1) with Temsirolimus in doses from 25 to 75 mg in phase I and 50 mg Temsirolimus in phase II, added on day 1, 8, 15 of a 28 days cycle. The primary endpoint of the phase II was ORR at the end of treatment.
View Article and Find Full Text PDFIn this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I.
View Article and Find Full Text PDF